Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer June 23, 2020June 23, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmailAgreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test Related News: FDA Approves NGS-Based Companion Diagnostic for EGFR…Roche receives FDA approval for first companion…U.S. FDA approves Foundation Medicine’s…Thermo Fisher Scientific & Pfizer Partner to…Ad hoc announcement pursuant to Art. 53 LR Roche…CHMP recommends EU approval of Roche’s Tecentriq as…
